R1	Has_qualifier Arg1:T1 Arg2:T2	
*	OR T1 T4
R2	Has_qualifier Arg1:T4 Arg2:T3	
R3	Has_qualifier Arg1:T5 Arg2:T6	
R4	Has_qualifier Arg1:T7 Arg2:T8	
R5	Subsumes Arg1:T9 Arg2:T10	
R6	Subsumes Arg1:T11 Arg2:T12	
R7	Subsumes Arg1:T14 Arg2:T15	
R8	Subsumes Arg1:T16 Arg2:T17	
*	OR T9 T11 T13 T14 T16 T18
R9	Subsumes Arg1:T7 Arg2:T9	
R10	Has_qualifier Arg1:T20 Arg2:T21	
*	OR T22 T23
R11	AND Arg1:T22 Arg2:T24	
R12	Has_qualifier Arg1:T27 Arg2:T26	
R13	Has_temporal Arg1:T27 Arg2:T28	
*	OR T20 T22 T27
R14	Has_qualifier Arg1:T30 Arg2:T32	
R15	Has_multiplier Arg1:T30 Arg2:T31	
R16	Has_qualifier Arg1:T34 Arg2:T35	
R17	Has_multiplier Arg1:T34 Arg2:T36	
*	OR T29 T30 T34
T1	Condition 21 34	complications
T2	Qualifier 14 20	severe
T3	Qualifier 38 44	severe
T4	Condition 45 54	infection
T5	Condition 57 65	Invasion
T6	Qualifier 69 91	central nervous system
T7	Condition 115 128	heart disease
T8	Qualifier 108 114	severe
T9	Condition 148 171	ventricular tachycardia
T10	Condition 173 175	VT
T11	Condition 178 197	atrial fibrillation
T12	Condition 199 201	AF
T13	Condition 204 215	heart block
T14	Condition 217 238	myocardial infarction
T15	Condition 240 242	MI
T16	Condition 245 269	congestive heart failure
T17	Condition 271 274	CHF
T18	Condition 277 299	coronary heart disease
T20	Condition 347 355	allergic
T21	Qualifier 340 346	severe
T22	Condition 387 395	allergic
T23	Condition 402 412	intolerant
T24	Procedure 436 457	chemotherapy regimens
T26	Qualifier 464 469	other
T27	Condition 470 486	malignant tumors
T28	Temporal 494 506	past 5 years
T29	Drug 527 538	doxorubicin
T30	Drug 573 583	adriamycin
T31	Multiplier 588 607	more than 300 mg/m2
T32	Qualifier 548 569	total cumulative dose
T33	Drug 0 8	Patients
T34	Drug 634 644	epirubicin
T35	Qualifier 609 630	total cumulative dose
T36	Multiplier 649 668	more than 450 mg/m2
T37	Competing_trial 671 717	Patients participate in other clinical studies
T38	Non-query-able 720 769	Other patients who are not suitable for the study
